antibody-drug conjugation
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive
Medicus Pharma completes patient enrolment for basal cell carcinoma trial
Interim results have shown over 60% clinical clearance in patients treated with SkinJect
Researchers at University of Geneva develop test platform for cancer treatments
The new platform could speed up testing while reducing the need for animal models
Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug
Cladribine capsules could become the first ever oral treatment for gMG
Merck and Blackstone agree on funding for cancer protein antibody
The funding will support late-stage clinical development of the investigational antibody-drug conjugate
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Eli Lilly’s Inluriyo approved by FDA for breast cancer
The oral drug can be used to treat advanced or metastatic breast cancer
Lilly and Circle Pharma agree to collaborate on new oral macrocycle therapies
The agreement is part of the Lilly Catalyze360 model, designed to empower early-stage biotechs